The Future Is Now
This year saw the shaky rollout of a revamped, post-patent-cliff pharmaceutical industry that may need time to gain traction
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
December 9, 2013 Cover
Volume 91, Issue 49
This year saw the shaky rollout of a revamped, post-patent-cliff pharmaceutical industry that may need time to gain traction
Cover image:
This year saw the shaky rollout of a revamped, post-patent-cliff pharmaceutical industry that may need time to gain traction
NSF census, two years into a revamp, has more details about chemistry department funding sources
Unproven therapies, cosmetics present challenges for regulators worldwide
TABLE: Ranks top chemical engineering spenders and breaks down funding sources.
TABLE: Few of chemistry's top spenders place in the overall top 25.
TABLE: Roughly three-quarters of spending came from federal funds in 2011.
As the legalization of marijuana spreads across the U.S., labs Sprout up to offer chemical analyses of cannabis products